DDIT4 is also highly expressed in malignant cancers,(23, 44) despite its known mTOR‐inhibiting properties, suggesting that some cancers have evolved mechanisms to resist DDIT4, which may also antagonize antitumor therapies. The gene discussed is DDIT4; the disease is cancer.